Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets

Core Insights - Arcturus Therapeutics Holdings Inc. (ARCT) is highlighted as a promising investment opportunity, particularly due to its undervaluation in the biotech sector [2][3]. Company Overview - Arcturus Therapeutics is a biotechnology company focused on developing mRNA-based vaccines and RNA therapeutics, utilizing proprietary delivery technologies [4]. - The company's pipeline addresses infectious diseases such as COVID-19 and influenza, as well as rare liver and respiratory disorders [4]. Market Analysis - Roth Capital initiated coverage of ARCT with a Buy rating and a price target of $20, indicating that the company's mid-stage programs have significant clinical activity and peak sales potential exceeding $1 billion [2]. - Roth noted that ARCT shares are trading near their cash value, implying a 0% chance of success for its pipeline assets, suggesting that the stock may be mispriced in the rare disease sector [2]. - Citigroup recently lowered its price target for ARCT from $9 to $7 while maintaining a Neutral rating, emphasizing opportunities in SMID-cap biotech for 2026, especially for companies nearing commercialization [3].